05/20/2021
Update: On February 9, 2021, the Ontario Superior Court of Justice dismissed the action on consent of the parties. The dismissal followed an evolution in the science since the action commenced that gave rise to considerable uncertainty regarding a causal link between Accutane use and IBD. This in turn also led to the dismissal of Accutane-related litigation in the United States. To read the Court’s decision, please click file:///C:/Users/dbj/Downloads/Patkus-v-Hoffman-discontinuance-Reasons-for-Decision%20(1).pdf. To see the order, please click fil:///C:/Users/dbj/Downloads/Patkus-v-Hoffman-discontinuance-order.pdf .
**Please note that dismissal of this proposed class proceeding may impact the limitation period applicable to any potential claims related to Accutane. Please seek legal advice immediately if you are thinking of starting an action.**